Business
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc.
About this update from Alpha Cognition Inc.
[{"type":"text","content":"\nManagement to host conference call on Thursday, March 26, 2026 at 4:30pm ET\n\n\n VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--\nAlpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close.\n\n\nThe company will issue a press release detailing its fourth quarter and full year financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/.\n\n\nFollowing the release, management will host a conference call to review financial and operating results.\n\n\nConference Call Information:\n\n\nTo participate in the conference call, please use the dial-in information below:\n\n\nParticipant Listening: 1-877-407-9039 or 1-201-689-8470\n\n\nor\n\n\nhttps://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6\n\n\nParticipants can use guest dial-in #s above and be answered by an operator, or click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.\n\n\nThe live audio webcast will be accessible here:\n\n\nhttps://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0\n\n\nA replay of the earnings call is available after the conference call has ended.\n\n\nReplay Dial-In:\n\n\n1-844-512-2921 or 1-412-317-6671\n\n\nAccess ID: 13758917\n\n\nReplay Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0\n\n\nAbout Alpha Cognition Inc.\n\n\nAlpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.\n\n\nZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated f...